Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Bioverativ
Fierce Pharma
Sanofi buys Blueprint for $9.1B, its largest deal in 7 years
After signaling its intent to make "bolt-on acquisitions," Sanofi has taken a major plunge, buying out Blueprint Medicines for $9.5 billion.
Kevin Dunleavy
Jun 2, 2025 11:09am
GBT adds 2 Sanofi sickle cell meds in deal worth up to $353M
Mar 16, 2021 9:55am
Sanofi nabs speedy review of sutimlimab
May 15, 2020 8:15am
Ex-Bioverativ CEO John Cox lands at Torque Therapeutics
Oct 2, 2019 7:43am
